Rhythm Pharmaceuticals (RYTM) EBIT (2020 - 2025)
Historic EBIT for Rhythm Pharmaceuticals (RYTM) over the last 6 years, with Q3 2025 value amounting to -$52.7 million.
- Rhythm Pharmaceuticals' EBIT fell 1997.95% to -$52.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$186.2 million, marking a year-over-year increase of 2986.91%. This contributed to the annual value of -$265.5 million for FY2024, which is 4401.57% down from last year.
- As of Q3 2025, Rhythm Pharmaceuticals' EBIT stood at -$52.7 million, which was down 1997.95% from -$45.3 million recorded in Q2 2025.
- In the past 5 years, Rhythm Pharmaceuticals' EBIT ranged from a high of -$34.4 million in Q1 2021 and a low of -$139.9 million during Q1 2024
- For the 5-year period, Rhythm Pharmaceuticals' EBIT averaged around -$49.7 million, with its median value being -$44.2 million (2021).
- As far as peak fluctuations go, Rhythm Pharmaceuticals' EBIT plummeted by 16629.42% in 2024, and later soared by 6639.86% in 2025.
- Over the past 5 years, Rhythm Pharmaceuticals' EBIT (Quarter) stood at -$51.0 million in 2021, then rose by 17.43% to -$42.1 million in 2022, then grew by 1.99% to -$41.3 million in 2023, then rose by 0.02% to -$41.3 million in 2024, then decreased by 27.63% to -$52.7 million in 2025.
- Its EBIT stands at -$52.7 million for Q3 2025, versus -$45.3 million for Q2 2025 and -$47.0 million for Q1 2025.